RenalTech makeover
This article was originally published in The Gray Sheet
Executive Summary
Firm initiates 55-patient clinical trial of BetaSorb dialysis enhancement device under new President and CEO Al Kraus. Kraus directed Gambro's IPO and took hemodialysis manufacturer Althin public prior to acquisition by Baxter. RenalTech now will be known as MedaSorb, to highlight non-dialysis uses of the adsorbent polymer technology as CytoSorb...